Literature DB >> 29710201

Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.

Bo Huang1, Lu Tian2, Enayet Talukder1, Mace Rothenberg3, Dae Hyun Kim4, Lee-Jen Wei5.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29710201      PMCID： PMC6584319          DOI： 10.1001/jamaoncol.2018.0275

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  Analysis of duration of response in oncology trials.

Authors:  Stuart Ellis; Kevin J Carroll; Kristine Pemberton
Journal:  Contemp Clin Trials       Date:  2007-11-12       Impact factor: 2.226

2.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

3.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

4.  Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors:  Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777
  4 in total
  8 in total

1.  Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.

Authors:  Bo Huang; Lu Tian; Zachary R McCaw; Xiaodong Luo; Enayet Talukder; Mace Rothenberg; Wanling Xie; Toni K Choueiri; Dae Hyun Kim; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

2.  Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Authors:  Lu Tian; Bo Huang; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2022-01-01       Impact factor: 31.777

3.  Appropriate Analysis of Duration of Response Data in Cancer Trials.

Authors:  Zachary R McCaw; Lu Tian; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2020-12-01       Impact factor: 31.777

4.  Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.

Authors:  Thomas Kelleher; Junliang Cai; Nicholas Aj Botwood; Dominic F Labriola
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

5.  Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.

Authors:  Peey-Sei Kok; Won-Hee Yoon; Sally Lord; Ian Marschner; Michael Friedlander; Chee Khoon Lee
Journal:  JCO Precis Oncol       Date:  2021-07-15

6.  Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Meredith M Regan; Lillian Werner; Sumati Rao; Komal Gupte-Singh; F Stephen Hodi; John M Kirkwood; Harriet M Kluger; James Larkin; Michael A Postow; Corey Ritchings; Mario Sznol; Ahmad A Tarhini; Jedd D Wolchok; Michael B Atkins; David F McDermott
Journal:  J Clin Oncol       Date:  2019-09-09       Impact factor: 44.544

7.  Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.

Authors:  Chen Hu; Meihua Wang; Cai Wu; Heng Zhou; Cong Chen; Scott Diede
Journal:  JAMA Netw Open       Date:  2021-05-03

8.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

Authors:  T K Choueiri; R J Motzer; B I Rini; J Haanen; M T Campbell; B Venugopal; C Kollmannsberger; G Gravis-Mescam; M Uemura; J L Lee; M-O Grimm; H Gurney; M Schmidinger; J Larkin; M B Atkins; S K Pal; J Wang; M Mariani; S Krishnaswami; P Cislo; A Chudnovsky; C Fowst; B Huang; A di Pietro; L Albiges
Journal:  Ann Oncol       Date:  2020-04-25       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.